Form 4: Coherus Oncology Director Receives Equity Grant

Director Rita A. Karachun was granted 30,000 restricted stock units and 60,000 stock options by Coherus Oncology, Inc.

Summary

• Director Rita A. Karachun acquired 30,000 restricted stock units (RSUs) on June 5, 2026.
• The reporting person was also granted 60,000 stock options with an exercise price of $1.45 per share.
• The RSUs vest 100% on the one-year anniversary of June 3, 2026.
• The stock options vest and become exercisable 100% on June 3, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Retention of board leadership through multi-year vesting schedules.

Negatives

• Potential future dilution of existing shareholders upon the exercise of options and vesting of RSUs.

Risks

• Vesting is contingent upon the reporting person's continued service relationship with the issuer.

Future Outlook

The equity grants are subject to continued service requirements, indicating a focus on long-term director retention.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board alignment with long-term shareholder value.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard practices for mid-cap biotechnology firms.
• The grant size is typical for non-employee director compensation packages in the industry.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of RSUs on June 3, 2027.
• Vesting of stock options on June 3, 2027.

Key Dates

Keywords

Coherus Oncology, CHRS, Form 4, Insider Trading, Equity Compensation, Director Compensation